Vanda granted public hearing to review FDA denying Hetlioz for jet lag
Source: SeekingAlpha
2026-03-03 16:40:28 ET
More on Vanda Pharmaceuticals
- Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy
- Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week
- Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript
- Vanda skin disorder drug accepted for FDA review
- Vanda surges as FDA approves Bysanti for bipolar disorder, schizophrenia
Read the full article on Seeking Alpha
For further details see:
Vanda granted public hearing to review FDA denying Hetlioz for jet lag
Vanda Pharmaceuticals Inc.
NASDAQ: VNDA
VNDA Trading
14.57% G/L:
$9.67 Last:
2,612,169 Volume:
$8.95 Open:
VNDA Latest News
March 03, 2026 08:01:00 am
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
February 26, 2026 04:35:00 pm
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
February 25, 2026 07:18:00 am
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
February 23, 2026 02:31:32 pm
Vanda Pharmaceuticals Stock Surges Following FDA Approval of New Psychiatric Drug
VNDA Stock Data
$442,042,792
53,186,967
3.95%
43
N/A
Biotechnology & Life Sciences
Healthcare
US
Washington
